---
title: "Wuxi Biologics Expects 2025 Revenue to Rise 16.7% to RMB21.79 Billion"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/275524625.md"
datetime: "2026-02-10T23:31:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275524625.md)
  - [en](https://longbridge.com/en/news/275524625.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275524625.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/275524625.md) | [English](https://longbridge.com/en/news/275524625.md)


# Wuxi Biologics Expects 2025 Revenue to Rise 16.7% to RMB21.79 Billion

WuXi Biologics (Cayman) Inc. announced that, based on a preliminary assessment of its unaudited consolidated management accounts for the year ended December 31, 2025, the company’s revenue is expected to increase by approximately 16.7% to RMB21,790 million. The gross profit margin rate is anticipated to expand by about 5 percentage points to 46.0%. Adjusted gross profit is projected to reach approximately RMB10,638 million, representing a year-on-year increase of around 25.5%. The company attributes these positive results to factors such as the ramp-up of its European manufacturing facility, cost savings and efficiency improvements from its business system and digitalization initiatives, as well as investment gains from its portfolio. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics (Cayman) Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260211-12021316), on February 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### 相關股票

- [Direxion S&P Biotech Bear 3X (LABD.US)](https://longbridge.com/zh-HK/quote/LABD.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-HK/quote/IBBQ.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [WuXi Biologics (WXXWY.US)](https://longbridge.com/zh-HK/quote/WXXWY.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-HK/quote/IXJ.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md)

## 相關資訊與研究

- [BUZZ-Context Therapeutics rises as FDA grants fast-track status to ovarian cancer drug](https://longbridge.com/zh-HK/news/281517197.md)
- [Telomir seeks FDA approval for Telomir-1 to treat breast cancer](https://longbridge.com/zh-HK/news/281346305.md)
- [Telomir submits IND for Telomir-1 to treat advanced and metastatic TNBC](https://longbridge.com/zh-HK/news/281174396.md)
- [Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KURA Stock News](https://longbridge.com/zh-HK/news/281632456.md)
- [Regeneron Gets FDA OK for Extended Eylea HD Dosing](https://longbridge.com/zh-HK/news/281556416.md)